Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases

作     者：Yuxi Wei Yan Xu Mengzhao Wang 

作者机构：Department of Respiratory and Critical Care MedicinePeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Peking Union Medical College(PUMC)and Chinese Academy of Medical SciencesBeijing 100730China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第13期

页      面：1523-1531页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Youth Program of the National Natural Science Foundation of China(No.82003309) 

主　　题：Non-small cell lung cancer Brain metastases Immune checkpoint inhibitor Tumor immune microenvironment 

摘      要：Lung cancer has the highest risk of brain metastasis(BM)among all solid *** emergence of BM has a significant impact on the selection of oncologic treatment for *** checkpoint inhibitors(ICIs)are the most promising treatment option for patients without druggable mutations and have been shown to improve survival in patients with non-small cell lung cancer(NSCLC)BM in clinical trials with good ***,ICI has shown certain effects in NSCLC BM,and the overall intracranial efficacy is comparable to extracranial ***,a proportion of patients showed discordant responses in primary and metastatic lesions,suggesting that multiple mechanisms may exist underlying ICI activity in *** to studies pertaining to tumor immune microenvironments,ICIs may be capable of provoking immunity in ***,systematic immune cells activated by ICIs can migrate into the central nervous system and exert antitumor *** review summarizes the present evidence for ICI treatment efficacy in NSCLC BM and proposes the possible mechanisms of ICI treatment for NSCLC BMs based on existing evidence.